| Trial ID: | L3250 |
| Source ID: | NCT05367063
|
| Associated Drug: |
Canagliflozin 100mg Or Sitagliptin 100mg
|
| Title: |
Canagliflozin and Myocardial Fibrosis
|
| Acronym: |
|
| Status: |
COMPLETED
|
| Study Results: |
NO
|
| Results: |
|
| Conditions: |
Type 2 Diabetes|Cardiovascular Diseases|Cardiac Perfusion Defect
|
| Interventions: |
DRUG: Canagliflozin 100mg or Sitagliptin 100mg
|
| Outcome Measures: |
Primary: Change in myocardial fibrosis Changes in myocardial fibrosis, The rate of ventricular extracellular volume and late gadolinium enhancement measured by MRI, 26 weeks since the randomization | Secondary: 1. Change in heart structures, The rate of Left Ventricular Mass Index (LVMI, , g/m2 ) measured by MRI., 26 weeks since the randomization|2. Change in resting mocardial blood flow, The rate of resting myocardial blood flow (MBF, ml/min) measured by MRI, 26 weeks since the randomization
|
| Sponsor/Collaborators: |
Sponsor: Shanghai Zhongshan Hospital
|
| Gender: |
ALL
|
| Age: |
ADULT, OLDER_ADULT
|
| Phases: |
PHASE4
|
| Enrollment: |
54
|
| Study Type: |
INTERVENTIONAL
|
| Study Designs: |
Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: BASIC_SCIENCE
|
| Start Date: |
2022-01-05
|
| Completion Date: |
2025-03-20
|
| Results First Posted: |
|
| Last Update Posted: |
2025-04-15
|
| Locations: |
Zhongshan Hospital, Fudan University, Shanghai, Shanghai, 200000, China
|
| URL: |
https://clinicaltrials.gov/show/NCT05367063
|
